Ion Exchange executes Technology Transfer Agreement with MANN + HUMMEL for PVDF membranes
Ion Exchange (India) Limited has executed a Technology Transfer Agreement with MANN + HUMMEL for the manufacture of PVDF Ultrafiltration membranes and Integrated Membrane Bioreactor systems. The collaboration involves a 7.50% technology transfer fee on revenue generated from manufactured products and will strengthen Ion Exchange's HYDRAMEM® solutions portfolio while enabling locally manufactured, globally benchmarked membrane technology.

*this image is generated using AI for illustrative purposes only.
Ion Exchange (India) Limited has executed a Technology Transfer Agreement with MANN + HUMMEL for the manufacture of PVDF Ultrafiltration (UF) membranes and Integrated Membrane Bioreactor (MBR) systems. The agreement was announced pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on April 29, 2026.
Agreement Details
The collaboration encompasses both domestic and international operations. Under the agreement, MANN + HUMMEL will transfer technology for the production of advanced PVDF hollow fiber ultrafiltration membranes with integrated UltraSKID systems, followed by technology transfer for Membrane Bioreactor solutions for deployment in India.
| Parameter: | Details |
|---|---|
| Technology Transfer Fee: | 7.50% on revenue generated from manufactured products |
| Related Party Transaction: | Not a related party transaction |
| Scope: | Manufacturing, system integration, and commercialization of PVDF UF membranes |
| Production Location: | Ion Exchange's expanded HYDRAMEM® facility in Goa |
Production and Strategic Benefits
Production will be conducted at Ion Exchange's expanded HYDRAMEM® membrane manufacturing facility in Goa. The agreement includes the transfer of technical know-how, covering manufacturing processes, formulations, and best practices. Ion Exchange will manufacture, undertake system integration, and commercialize PVDF hollow fiber ultrafiltration membranes along with integrated UltraSKID systems based on MANN+HUMMEL's advanced technology.
Expected Benefits and Rationale
The collaboration strengthens Ion Exchange's HYDRAMEM® solutions to offer an integrated portfolio of membrane-based technologies, including Ultrafiltration (UF), Reverse Osmosis (RO) and Membrane Bioreactor (MBR) systems. The strategic partnership aims to enable the delivery of globally benchmarked membrane technology manufactured locally, reduce import dependence, and ensure improved supply reliability with faster delivery timelines for customers.
Regulatory Compliance Details
The agreement has been entered into in the ordinary course of business and is expected to support the Company's long-term strategic and technological objectives. The disclosure was made in compliance with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, providing comprehensive details of the strategic technology transfer and manufacturing collaboration.
Historical Stock Returns for Ion Exchange
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.23% | -3.26% | +18.95% | -0.40% | -23.43% | +112.02% |
How will this technology transfer impact Ion Exchange's competitive positioning against international membrane manufacturers in the Indian market?
What is the expected timeline for Ion Exchange to achieve full production capacity and begin generating significant revenue from the PVDF membrane manufacturing?
Could this partnership lead to Ion Exchange becoming a regional manufacturing hub for MANN + HUMMEL's membrane technologies in South Asia?


































